QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and mechanism of action of multiple doses
of QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis